CytomX Therapeutics, Inc.

126 articles with CytomX Therapeutics, Inc.

• CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock - Jan 21, 2021

  1/21/2021

  CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, announced the pricing of an underwritten public offering of 14,285,714 shares of its common stock at a price to the public of $7.00 per share, for gross proceeds of $100 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by CytomX.

• CytomX Therapeutics Announces Proposed Public Offering of Common Stock

  1/19/2021

  CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has commenced an underwritten public offering of $75.0 million of its common stock.

• CytomX Therapeutics Announces New Employment Inducement Grants - Jan 19, 2021

  1/19/2021

  CytomX Therapeutics, Inc. announced that on January 15, 2021, the Company granted two new employees options to purchase a total of 98,000 shares of the Company’s common stock at an exercise price per share equal to $7.93, which was the closing trading price on January 15, 2021, the date of the grant.

• CytomX Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/7/2021

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on January 14 th at 11:40 a.m. ET.  CytomX Thera

• CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors

  12/22/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced the appointment of Mani Mohindru, PhD to the Company’s board of directors. Dr. Mohindru brings to CytomX deep and varied experience across the life sciences industry, with particular experience in finance and

• CytomX Therapeutics to Present Updates on CX-2009 at 2020 San Antonio Breast Cancer Symposium

  12/3/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced two poster presentations at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) taking place from December 8-11, 2020

• CytomX Therapeutics to Present at Upcoming Investor Conferences

  11/11/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual healthcare conferences in November. Jefferies Virtual London Healthcare Conference

• 

  Clinical Catch-Up: November 2-6

  11/9/2020

  It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.

• CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate

  11/5/2020

  Advancement Follows ASCO 2020 Data Validating CD71 as an Anti-Cancer Target and Supporting Phase 2 Development Strategy of Potential First-in-Class Drug Candidate

• CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business UpdateCompany to host a conference call today, November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT

  11/5/2020

  CytomX Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, reported third quarter 2020 financial results and provided a business update.

• CytomX Therapeutics to Announce Third Quarter 2020 Financial Results-Teleconference Scheduled for November 5, 2020, at 5:00 p.m. ET / 2:00 p.m. PT-

  10/29/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, plans to report second quarter 2020 financial results on Thursday, November 5, 2020, after the close of U.S. markets.

• CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D.

  10/6/2020

  CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody ® technology platform, today announced the planned retirement from CytomX of W. Michael Kavanaug

• CytomX Therapeutics Announces New Employment Inducement Grants - Sep 18, 2020

  9/18/2020

  CytomX Therapeutics, Inc. announced that on September 15, 2020, the Company granted nine new employees options to purchase a total of 211,000 shares of the Company’s common stock at an exercise price per share equal to $7.22, which was the closing trading price on September 15, 2020, the date of the grant.

• CytomX Therapeutics to Participate in Upcoming Healthcare Conferences

  9/2/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual healthcare conferences in September.

• CytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update Company to Host a Conference Call Today, August 6, 2020, at 5:30 p.m. ET / 2:30 p.m. PT

  8/6/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today reported second quarter 2020 financial results and provided a business update.

• CytomX Therapeutics to Participate in the 2020 Wedbush PacGrow Healthcare Conference

  8/4/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate in the 2020 Wedbush PacGrow Virtual Healthcare Conference. Dr. McCarthy will present a Corporate

• CytomX Therapeutics to Announce Second Quarter 2020 Financial Results-Teleconference Scheduled for August 6, 2020, at 5:30 p.m. ET-

  7/28/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, plans to report second quarter 2020 financial results on Thursday, August 6, 2020, after the close of U.S. markets. Following the announcement, the company will host a conference call beginning at 5:30 p.m. ET to

• CytomX Therapeutics Announces Preclinical Data from Anti-CTLA-4 Probody Therapeutic Programs Presented by Partner Bristol Myers Squibb at AACR Annual Meeting

  6/22/2020

  Preclinical Data Supports Expanded Therapeutic Index and Provides Rationale for Ongoing Clinical Studies

• CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program

  5/29/2020

  - First Presentation of Clinical Data for CX-2029, a Probody Drug Conjugate,  Directed Against CD71: A Previously Undruggable Target - - Data Updates for CX-2009 Support Phase 2 Investigations in Breast Cancer - - Favorable Tolerability Profile Demonstrated for Anti-PD-L1 and Anti-CTLA-4 Probody Therapeutics - - Company to Host Webcast Today, -

• CytomX Therapeutics to Participate at Upcoming Healthcare Conferences

  5/28/2020

  CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate in the following virtual healthcare conferences in June.